Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.
about
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancerMitochondrial fatty acid oxidation in obesityAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Carnitine Palmitoyltransferase 1b Deficiency Protects Mice from Diet-Induced Insulin ResistanceNonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism.The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and MonkeysHepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation.A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.Use of dicarboxylic acids in type 2 diabetes.Dissociating fatty liver and diabetesPre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems.Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting.Time sequence of the intensification of the liver glucose production induced by high-fat diet in mice.Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance.
P2860
Q26747750-653E2720-876A-490F-9519-701767E562E5Q26820838-DC049C30-57FC-4D41-B8F5-2BA2EDACB636Q26830274-DD3FDA18-C4CF-45E9-B260-94E3A67331D1Q30426407-FA4E53A2-3E7D-4EA0-8B27-C72F17527E43Q30597265-89B66156-AD79-4DAB-9ED8-9689C3E142D1Q34307835-D2A2DB40-A390-4F54-9493-8330C3ADB506Q34412650-40A0DC98-31EB-4903-A96B-2D21061B810AQ35796087-E623C8BE-9C28-44AC-8855-8B82C6E51AB4Q36151024-53D5C318-608D-4F31-92B9-C337EB673EBDQ36482932-D783BF78-4ECE-421B-A929-33C516BE3411Q37722693-4AD3D99B-70AB-400D-815B-404D3CAA0D70Q37975520-885F6567-B47A-43B2-BFF7-C8FA5B3B61CAQ38050214-B69FD7AB-3ADB-4F40-B551-1BE09BC490A8Q39280379-C09AD412-FEC4-4E81-8277-9AED59129797Q39572533-C4DFAD8E-C77A-4103-9193-3CE819B077F5Q51361385-35366895-6D9B-4711-8F96-C08AF08B43ABQ55230187-B6473767-F68F-45E8-A17C-72EE5D25FFA7
P2860
Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Selective reversible inhibitio ...... improves glucose homeostasis.
@ast
Selective reversible inhibitio ...... improves glucose homeostasis.
@en
Selective reversible inhibitio ...... improves glucose homeostasis.
@nl
type
label
Selective reversible inhibitio ...... improves glucose homeostasis.
@ast
Selective reversible inhibitio ...... improves glucose homeostasis.
@en
Selective reversible inhibitio ...... improves glucose homeostasis.
@nl
prefLabel
Selective reversible inhibitio ...... improves glucose homeostasis.
@ast
Selective reversible inhibitio ...... improves glucose homeostasis.
@en
Selective reversible inhibitio ...... improves glucose homeostasis.
@nl
P2093
P2860
P356
P1433
P1476
Selective reversible inhibitio ...... improves glucose homeostasis.
@en
P2093
Arduino Arduini
Edoardo Mannucci
Emanuela Tassoni
Fabio Giannessi
Paolo Carminati
Pompeo Pessotto
Roberto Conti
P2860
P304
P356
10.2337/DB10-0346
P407
P577
2011-02-01T00:00:00Z